Rationale: Accumulating data support a therapeutic role for mesenchymal stem cell (MSC) therapy; however, there is no consensus on the optimal route of delivery.
C ardiovascular disease, which can lead to myocardial infarction (MI) and heart failure, is the leading cause of death worldwide. 1 Current standard therapies succeed only in temporarily managing the disease, illustrating the need for novel approaches to prevent and reverse cardiac dysfunction. Cell-based therapy displays remarkable regenerative promise for repairing cardiac damage post-MI. 2 Specifically, mesenchymal stem cells (MSCs) have produced significant and encouraging results for a variety of pathological conditions, including MI in both preclinical studies 2 and clinical trials. [3] [4] [5] [6] [7] [8] MSC-based therapies are currently used to treat both acute MI (AMI) and chronic ischemic cardiomyopathy (ICM), which are thought to work by activating endogenous tissue repair through paracrine signaling and exhibiting immunomodulatory properties, reducing immune-mediated damage after MI. 9 For example, MSCs are antifibrotic and produce left ventricular (LV) reverse remodeling in preclinical models. 10 More importantly, MSCs improve patient functional status and quality of life. 8, 11, 12 Large animal models, specifically swine, are better predictors of response to MSC therapy in humans because of their longer life span and similarities in immune system properties 13 and cardiac function.
MSC translational research has focused mainly on AMI animal models, but there has been a shift toward also investigating ICM models. 10 MSC immunomodulatory properties and paracrine secretion reduce inflammation, protect compromised viable tissue, and stimulate cellular growth, proliferation, and differentiation to help prevent and reverse ischemic injury in AMI. [15] [16] [17] MSCs prevent the initial cardiac damage of AMI before it progresses to pathological remodeling of the heart. 17 MSC therapy for ICM focuses on reducing scar size and promoting endogenous tissue regeneration to reverse worsening cardiac dysfunction. 16 Reducing the infarct size (IS) improves the LV ejection fraction (LVEF) because a smaller area of scarred and akinetic myocardium results in less ventricular remodeling. 18 A large IS with significant ventricular remodeling leads to increased chamber volume in an attempt to maintain cardiac output and compensate for the loss of viable myocardium. These effects are followed by an eventual decline in ejection fraction and poor long-term prognosis. 19 In this meta-analysis, we discuss the beneficial effects of MSC therapy on AMI and ICM preclinical models and the implications for clinical intervention and therapies. We also assess the efficacy of different routes of MSC delivery, including transendocardial stem cell injection (TESI), direct intramyocardial injection (DI), intravenous infusion, and intracoronary infusion. TESI is a minimally invasive, catheter-based route of delivery, where cells are injected directly into the myocardium through the endocardium. DI is performed through a thoracotomy, and cells are injected into the myocardium through the epicardium. Intravenous infusion is the least invasive route; cells are infused into the venous blood supply and allowed to migrate toward the injured myocardium. Last, in intracoronary infusion, cells are infused into the coronary artery that supplies the infarcted myocardium. A recent review by Golpanian et al 20 concluded that there is a lack of consensus as to the optimal route of stem cell delivery, illustrating the need for further examination of the efficacy of these different routes.
Methods
The research protocol was based on the meta-analysis conducted by Zwetsloot et al. 21 Specifically, we performed a search of PubMed and Embase with the terms: myocardial infarction, mesenchymal stem cell, and animal models (Figure 1, flowchart) . Clinical trials were found via clinicaltrials.gov and searching PubMed and Embase using the terms: myocardial infarction, mesenchymal stem cell, and clinical trials. Studies were screened by 2 independent investigators (A.J.K., J.L.) in the title-abstract and full-text screen. A third investigator (C.P.) was consulted in case of no consensus on inclusion. In addition, references and other sources were examined to find any other suitable studies based on the inclusion criteria. Only studies published in English were included. The studies were carefully examined to exclude overlapping data. Studies were included if they reported a placebo-controlled MI animal model (mouse, rat, or swine) where bone marrow-derived MSCs were administered and in which LVEF or IS was used as a parameter. We were interested in the effect of unmodified MSCs, so we excluded any pretreated, genetically engineered, or transfected cells. AMI mouse, rat, and swine models were analyzed, as well as AMI clinical trials. ICM was only analyzed in swine models because of the small number of trials in mice, rats, and humans. Stem cells were transplanted ≤1 week after MI in AMI animal models and ≥1 month after MI in ICM animal models. Studies What New Information Does This Article Contribute?
• Route of delivery modulates the efficacy of MSC therapy in acute myocardial infarction swine studies and clinical trials.
• MSCs administered via transendocardial stem cell injection improved cardiac function and appeared to be superior to direct intramyocardial injection, intravenous infusion, and intracoronary infusion.
MSCs are a promising therapy for treating both acute myocardial infarction and chronic ischemic cardiomyopathy in preclinical studies and clinical trials. Our meta-analysis examined 58 preclinical studies that included 1165 animals and 6 clinical trials with 334 patients and confirmed the therapeutic efficacy of MSC therapy. However, many questions remain as to optimizing treatment. Currently, there are 4 different routes of delivery for MSC therapy: transendocardial stem cell injection, direct intramyocardial injection, intravenous infusion, and intracoronary infusion. We tested the hypothesis that the route of MSC delivery influences the reduction in infarct size and improvement in left ventricular ejection fraction. We discovered that the route of delivery did indeed play an important role in the efficacy of MSC therapy. Transendocardial stem cell injection seems to be the most favorable route of delivery because of both its reduction in infarct size and improvement of left ventricular ejection fraction in acute myocardial infarction preclinical and clinical trials, which has important implications for the design of future studies.
were excluded if the time from MI to stem cell transplantation was subacute (>1 week but <1 month). We used LVEF and IS as our primary outcome measures and, therefore, excluded any studies that did not report an LVEF or IS measurement. Fractional shortening (FS), dose, and change (Δ) in IS (ΔIS) and LVEF (ΔLVEF) were used as secondary outcome measures. The studies measuring LVEF (% EF) used different methods such as echocardiography, magnetic resonance imaging, LV angiography, and single-photon emission computed tomography. We used the results provided by the studies, and no distinction was made as to methodology. For the analysis of multiple measurements (LVEF, IS, and FS), the time point furthest from cell transplantation was used because we deemed this approach to be the best predictor of functional outcome. For ΔIS and ΔLVEF, the final time points were standardized to improve homogeneity and reduce bias between studies-≤12 weeks for animal models and 24 weeks for clinical trials; baseline values were taken after MI. Studies with measurements of IS were determined by triphenyltetrazolium chloride stain, Masson Trichrome stain, or magnetic resonance imaging, which measured the scar volume as a percent of LV volume. As with LVEF, we obtained the information provided by the studies, and no distinction was made between different techniques. Subgroup analyses were conducted on routes of delivery to test for differences in efficacy. Differences in the number of administered MSCs were analyzed to control for dose as a confounding variable in regards to effect on IS and LVEF. In cases of missing data for our primary outcome measures, corresponding authors were contacted. Emails were sent to 16 authors; 8 responded.
Statistical Analysis
Meta-analyses were performed, and forest plots were generated using Revman v5.3 (Cochran Tech, London, United Kingdom). Random effects models were used throughout, because of the possible heterogeneity from sources such as the number of cells administered, autologous versus allogeneic stem cells, and differences in time for final end points. If SD was not provided by the studies, SEM was used to calculate the SD. If neither SD nor SEM were found, studies were excluded and deemed not estimable. Studies that were deemed not estimable because of missing data were displayed in the forest plots but were excluded from the statistical analyses. The outcomes measured by this study are only continuous variables and as such are represented as a mean difference with 95% confidence interval (95% CI) between groups. For studies that contained >2 treatment arms, only control and MSC groups were analyzed. Studies conducting >1 experimental group containing MSCs had their values pooled together using mean, SD, and size and were denoted by an asterisk (*).
Studies where P<0.05 were considered statistically significant, and 2-sided 95% CI was reported throughout the study. In addition, the I 2 statistic was used to assess for heterogeneity within the different subgroups. We use I 2 >25% as moderate heterogeneity and >75% as a high degree of heterogeneity. A sensitivity analysis was used to assess for risk of bias on significant results by excluding trials with unclear risk of performance bias, selection bias, or attrition bias. Studies that indicated a baseline value with no significant change were included in the analysis and noted with 2 asterisks (**). Studies that share the same first author and year were denoted with an up arrow (^). Metaregression was conducted for dose analysis using Stata 13 (StataCorp LP, College Station, TX); P <0.05 was considered significant, and 95% CI was used.
Results
Our final search was performed on August 8, 2016 (Figure 1 , flowchart). We identified 371 papers on PubMed and 597 on Embase. After removal of duplicates and title/abstract screening, 117 papers were selected for full-text screening. Fiftyeight papers were finally included, and a meta-analysis was performed on mouse, rat, and swine studies investigating the effect of MSC therapy on AMI and ICM (n=1165 animals). Characteristics of the enrolled animal studies are presented in the Online Table I . A similar meta-analysis was performed on 6 AMI clinical trials (n=334 patients), characteristics of which are depicted in Online Table II .
MSC Therapy Reduces IS in Animal Models
Nineteen rodent studies were examined to assess the efficacy of MSC therapy for reducing IS. Four mouse studies, comprised 28 treated and 29 control mice, were analyzed, and 2 of these studies favored MSC treatment, whereas 2 did not indicate a difference between treatment and control. Metaanalysis of these mouse studies revealed an 8.6% reduction in IS (95% CI, −12.5 to −4.8; Figure 2 ), thus favoring MSC treatment (P<0.0001). Fourteen rat studies (174 treated, 171 control rats) were analyzed for efficacy of MSC therapy in the reduction of IS. In 7 of these studies, rats receiving MSC treatment exhibited improved IS, whereas in 7 studies no difference was seen between the treated and control animals. Overall, there was an 8.3% greater reduction in IS (95% CI, −10.5 to −6.2; Figure 2 ) in treated animals compared with control, favoring MSC treatment (P<0.00001) and paralleling the results of the mouse studies.
Twelve AMI swine studies were analyzed for efficacy of MSC therapy in the reduction of IS. Seven of the studies favored MSC treatment, whereas 5 revealed no difference between treatment and control. Out of a total of 114 treated and 83 control swine, there was a 6.4% reduction in IS (95% CI, −11.9 to −0.9; Figure 2 ), demonstrating an overall improvement in MSC-treated animals compared with control (P=0.02). Six ICM swine studies (45 treated, 36 control swine) were analyzed for efficacy of MSC therapy in the reduction of IS; 4 favored MSC treatment, whereas 2 studies did not reveal a difference between treatment and control. There was a 6.0% reduction in IS in treated animals (95% CI, −9.7 to −2.4; Figure 2 ), thus favoring MSC treatment (P=0.001). Ultimately, there was a 7.1% reduction in IS for all MSC-treated animal models compared with control (361 treated, 319 control animals; 95% CI, −9.3 to −4.9; P<0.00001; Figure 2 ), favoring MSC therapy.
MSC Therapy Improves LVEF in Animal Models
Twenty-four rodent studies were examined to assess the efficacy of MSC therapy for improving LVEF. All 5 mouse studies analyzed favored MSC treatment. There was an improvement in LVEF for MSC-treated mice compared with control (49 treated, 46 control mice) by 12.2% (95% CI, 8.5 to 15.8; P<0.00001; Figure 3 ). In the 19 rat studies analyzed for efficacy of MSC therapy (263 treated, 234 control rats), 14 favored MSC treatment, whereas 5 studies resulted in no difference between treatment and control. There was a 12.6% improvement in LVEF in treated animals compared with control (95% CI, 8.4 to 16.7; P<0.00001; Figure 3) .
Sixteen AMI swine studies (135 treated, 112 control swine) were analyzed for efficacy of MSC therapy in the improvement of LVEF. Seven studies favored MSC treatment, whereas the other 9 studies did not demonstrate a difference between treatment and control. There was a 7.2% improvement in LVEF (95% CI, 4.1 to 10.3; Figure 3 ) in treated animals, thus favoring MSC treatment (P<0.00001). Furthermore, 8 ICM swine studies (53 treated, 48 control swine) were analyzed, 7 of which favored MSC treatment, whereas only 1 study did not reveal a difference between treatment and control. Accordingly, there was a 12.2% improvement in LVEF (95% CI, 7.9 to 16.4) with a preference toward MSC treatment (P<0.00001; Figure 3 ). Last, there was a 10.8% improvement of LVEF for all MSC-treated animal models compared with control (500 treated, 440 control animals; 95% CI, 8.6 to 13.0; P<0.00001; Figure 3 ), again favoring MSC therapy.
Route of Delivery Affects IS Reduction in AMI Swine Studies
We next assessed the influence of route of delivery on the therapeutic efficacy of MSCs in the reduction of IS in AMI swine studies. Twelve studies using 4 different cell delivery routes were examined: DI, TESI, intracoronary infusion, and intravenous infusion. One study assessed the efficacy of the DI route of MSC delivery for the reduction of IS, concluding that MSC treatment did not reduce IS compared with control (6 treated, 6 control swine); rather, it increased the IS by 1.0% (95% CI, −6.1 to 8.1; Figure 4 ), suggesting that DI is not a favorable route of delivery (P=0.78). All 3 studies using TESI favored MSC treatment compared with control. These studies revealed a 9.4% reduction in IS (95% CI, −15.9 to −3.0; Figure 4 ) in the 33 treated swine compared with the 16 controls, thus favoring TESI (P=0.004). Five studies were analyzed for the efficacy of the intracoronary infusion route of delivery, with 3 studies demonstrating that MSC treatment reduced IS compared with control, whereas 2 studies did not (37 treated, 35 control swine). There was a 7.1% reduction in IS (95% CI, −15.7 to 1.5; Figure 4 ) suggesting that intracoronary infusion is not a favorable route (P=0.11). Two out of 3 studies that used intravenous infusion did not reveal a difference between MSC treatment and control (38 treated, 26 control swine). There was a 3.4% decrease in IS (95% CI, −9.9 to 3.2; Figure 4 ), which did not favor intravenous infusion route of delivery (P=0.31).
Route of Delivery Affects LVEF Improvement in AMI Swine Studies
Similarly, we assessed the effect of route of delivery on improvement of LVEF in a total of 16 AMI swine studies. Six studies used DI, and 3 of these studies favored MSC treatment compared with control, whereas 3 studies did not reveal a difference. Out of 48 treated swine compared with 47 controls, there was an 8.8% improvement in LVEF (95% CI, 3.0 to 14.6; Figure 5 ), highlighting a preference toward DI (P=0.003). Four studies were analyzed for efficacy of TESI as a route of delivery. Two studies favored MSC treatment compared with control, whereas the other 2 did not reveal a difference. Out of 43 treated swine compared with 22 controls, there was a 9.1% improvement of LVEF (95% CI, 3.7 to 14.5; Figure 5 ), therefore, favoring TESI (P=0.0009). Five studies assessed the intracoronary infusion route of delivery of MSCs. Only 1 study favored MSC treatment versus control (37 treated, 35 control swine), whereas the remaining 4 studies did not reveal a difference. There was a 5.0% increase in LVEF (95% CI, −1.7 to 11.8; Figure 5 ), which did not favor intracoronary infusion (P=0.14). Only 1 study was analyzed in AMI swine models using intravenous infusion administration of cells, and it indicated a preference toward MSC treatment compared with control (7 treated, 8 control swine) with a 5.0% improvement in LVEF (95% CI, 2.5 to 7.6; Figure 5 ), thus favoring intravenous infusion (P=0.0001).
Route of Delivery Affects LVEF Improvement in AMI Clinical Trials
The route of MSC delivery on improvement of LVEF was examined in 6 AMI clinical trials, none of which used DI. The efficacy of TESI administration of MSCs was analyzed in 1 clinical trial, which favored MSC treatment compared with control. Out of a total of 8 treated patients compared with 30 controls, there was a 7.0% improvement in LVEF (95% CI, 2.7 to 11.3; Figure 6 ), thus favoring TESI (P=0.002). Four clinical trials were analyzed for efficacy of the intracoronary infusion route of delivery. One favored MSC treatment compared with control, whereas 3 clinical trials revealed no difference. Out of 113 treated patients compared with 115 controls, there was a 3.5% improvement in LVEF (95% CI, −2.4 to 9.5; Figure 6 ), a difference that was not statistically significant, suggesting that intracoronary infusion is not favorable (P=0.24). The efficacy of the intravenous infusion route of delivery was assessed in 1 clinical trial, which demonstrated a favorable effect of MSC treatment (39 patients) compared with control (21 patients). Specifically, there was a 5.6% improvement in LVEF (95% CI, 0.9 to 10.3; Figure 6 ), favoring intravenous infusion (P=0.02).
Meta-Analysis of Secondary Outcomes
For all secondary outcomes (FS, ΔIS, ΔLVEF, and dose), similar trends were observed, all favoring MSC therapy. FS was analyzed in 16 rat and swine studies (170 treated, 168 control), 12 of which favored MSC treatment, whereas 4 revealed no difference between treatment and control. Accordingly, there was an 8.2% improvement in FS (95% CI, 3.1 to 13.0) favoring MSC treatment (P<0.00001; Online Figure I ). For ΔIS, 8 swine studies (58 treated, 49 control) were analyzed, 6 of which favored MSC treatment, whereas 2 did not. Thus, 8 cells, with generally more cells used for larger animals (swine>rat>mouse). Metaregression showed no statistically significant difference for IS and LVEF when dose was taken into account for all preclinical studies (P=0.06 and P=0.15, respectively; data not shown). Metaregression specifically for AMI swine studies, which compared all 4 routes of delivery, also indicated that dose was not a significant predictor for IS and LVEF (P=0.54 and P=0.62, respectively; data not shown).
Discussion
We performed a meta-analysis of MSC therapy for 3 animal models: mouse, rat and swine. Our primary outcomes (IS and LVEF) revealed a reduction in IS and improvement of LVEF in all animal models treated with MSCs (Figures 2 and  3) . We also calculated ΔIS and ΔLVEF to normalize potential confounding factors, such as differences in baseline between control and treatment. Both ΔIS and ΔLVEF (Online Figures  II and III, respectively) revealed a similar improvement after MSC therapy. The AMI studies were also analyzed based on routes of delivery, including DI, TESI, intravenous infusion, and intracoronary infusion to identify differences. The route of delivery modulated the efficacy of MSC therapy in both AMI swine models and clinical trials. In AMI swine models, TESI produced more favorable results, revealing a reduction in IS, whereas DI, intracoronary infusion, and intravenous infusion indicated no improvement (Figure 4) . Similarly, TESI improved LVEF, as did DI and intravenous infusion, whereas intracoronary infusion delivery revealed no improvement ( Figure 5 ). In AMI clinical trials, changes of LVEF paralleled these results, with TESI again improving LVEF, as well as intravenous infusion, whereas intracoronary infusion indicated no improvement ( Figure 6 ). DI route of delivery has not been studied in AMI clinical trials. Our meta-analysis confirms that MSCs are an effective therapy for preserving cardiac function by reducing IS and improving LVEF in all 3 animal models (mouse, rat, and swine). Moreover, the meta-analysis compared AMI and ICM swine studies for improvement of IS and LVEF. AMI swine studies were analyzed based on route of delivery; however, there were not sufficient numbers of ICM swine studies to do a similar comparison. Likewise, there are few ICM clinical trials; therefore, a similar comparison for route of delivery is currently not possible.
Results of Phase I/II clinical trials illustrate that stem cell therapy is safe and efficacious for both AMI and ICM, and furthermore, that MSC therapy favorably affects patients' functional capacity, ventricular remodeling, and quality of life. 8, 11, 12, 22 Importantly, we demonstrated that the route of cell delivery modulated the efficacy of MSC therapy. Although the reasons for these differences are unclear, the advantages and disadvantages of each route of delivery are highlighted in Online Table III. DI is the most direct, precise, and accurate epicardial approach of injecting stem cells in and around the infarcted area of the heart. However, a swine study by Grossman et al 23 revealed that despite direct injection into the myocardium, there was a lower total cell retention rate when compared with TESI, Mean effect±SD of mesenchymal stem cells (MSCs; Treatment) or placebo/no treatment (Control) on the improvement of LVEF (%) based on the route of delivery: direct intramyocardial injection, TESI, intracoronary infusion, and intravenous infusion, in acute myocardial infarction (AMI) swine studies illustrating that TESI, direct intramyocardial injection, and intravenous infusion favor MSC treatment, whereas intracoronary infusion does not. Number of animals in each arm of the study (Total). Relative weight of each study (Weight). Mean difference between Treatment and Control with a 95% confidence interval (95% CI), using inverse variance (IV) and random effects model (Random).
because of leakage from the injection site during and after the DI procedure. The invasive nature of a thoracotomy is the biggest drawback for DI, with greater risks for complications and increased morbidity and mortality. 24 The gold standard of treatment for an AMI is percutaneous coronary intervention or medical management, not thoracotomy. Therefore, DI has not been investigated as a route of delivery in AMI clinical trials. DI can be performed during open heart surgery in coronary artery bypass grafting for heart failure, which explains why it has been investigated in ICM clinical trials.
TESI is a minimally invasive procedure that is feasible and safe, with continuous advancements in imaging and catheterization techniques. There are at least 5 different TESI catheter designs and 3 imaging platforms to guide the injections. In 2005, Amado et al 25 used the corkscrew-shaped needle Helix (Biocardia). The studies conducted from 2008 to 2010 [26] [27] [28] [29] used the straight needle Stiletto (Boston Scientific). All of these studies used conventional 2-dimensional projection x-ray fluoroscopy for imaging. The catheter delivery system has since progressed to the straight needle Myostar (Biosense Webster), which has been used in both translational and clinical trials from 2013 to 2015. 6, 10, 18, 30 The imaging technique also progressed to 3-dimensional electromechanical mapping of the left ventricle using the NOGA system (Biosense Webster). With TESI, the stem cells are injected directly into the myocardium through the endocardium. As with all techniques that require injection into the myocardium, there is a small risk of perforation and induction of arrhythmias. However, the benefits of TESI outweigh the risks compared with more invasive procedures such as DI, and many swine studies have shown TESI to be an efficacious route of delivery. 25, 28, 29, 31 Intravenous infusion cell delivery is the most convenient and least invasive route, used more often after AMI because of the preponderance of physiological homing signals which allow the cells to migrate toward the injured myocardium. 24 The biggest concern for the intravenous infusion route is the lack of implantation and retention in the infarcted region of the heart because cells are delivered through the systemic circulation, possibly accounting for intravenous infusion treatment not reducing IS compared with control. There is also an increased likelihood of the MSCs lodging and engrafting in other organs, particularly the lungs, or being eliminated by the reticuloendothelial system, including the spleen. 32 Intracoronary infusion delivery has the main advantage of delivering MSCs proximal to the infarcted myocardial regions through the appropriate coronary vessel. After the catheter is in position, a balloon is inflated to block the blood flow, which helps MSCs to adhere and transmigrate to the infarcted region of the myocardium. 2 An intrinsic disadvantage of this route is the difficulty of delivering cells into an area that is not well perfused, possibly explaining the lack of reduction of IS. In addition, there is a concern of inducing further ischemia by occluding the coronary artery. There is also a threshold for the number of cells that can be delivered before the possibility of embolization in the small coronary arteries and vascular microinfarcts. 33 In AMI swine models, TESI was the most favorable route of delivery for reduction of IS. TESI also revealed an improvement in LVEF, consistent with the decrease in IS. The results of TESI for IS and LVEF are promising and support conducting clinical trials using this modality for stem cell delivery. It is important to note that not only is TESI efficacious, but it is also a direct and minimally invasive procedure; therefore, TESI is the route of delivery that is most promising for clinical trials. Although DI revealed an improvement in LVEF, it did not demonstrate a reduction in IS, which may be because of lower total cell retention rate 23 when compared with TESI. The intravenous infusion route of delivery also indicated an improvement in LVEF, but similar to DI, it did not demonstrate a difference in IS. Of note, only 1 study investigated the intravenous infusion route of delivery, which makes it difficult to make firm conclusions. However, 1 potential explanation for these results is that the intravenous infusion route of delivery leads to a migration of MSCs toward the injured heart, but the MSCs do not engraft into the infarcted area. Instead, the MSCs may engraft onto the surrounding viable myocardial tissue, a less hypoxic environment, which may work to reduce ventricular remodeling and improve LVEF without necessarily reducing the IS. For intracoronary infusion delivery, no change in LVEF or reduction in IS was seen.
Although there have been few AMI clinical trials, we explored comparisons to the AMI swine studies. As previously stated, DI has not been investigated in AMI clinical trials. One clinical trial demonstrated that TESI was a favorable and efficacious route of delivery. 6 Intracoronary infusion did not seem to be an efficacious route of delivery in clinical trials. In 3 of 4 studies, no difference between treatment and control was seen, whereas Chen et al 3 indicated a difference, albeit a significant outlier, which we chose not to exclude because of the already low number of clinical trials conducted. It is possible that Chen et al 3 found such a striking difference because of the large number of cells injected, 6 mL containing 8 to 10×10
9 bone marrowderived MSCs/mL, compared with an average of 1×10 6 to 1×10 8 cells/mL in the other clinical trials. Therefore, the effect of dose on MSC therapy should be further explored, as seen with TESI in the POSEIDON clinical trial (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis). 11 The intravenous infusion route seems to be an effective method of delivery, revealing an improvement of the patients' LVEF, similar to the translational data for LVEF in AMI swine models. This result lends support to the hypothesis that the intravenous infusion route helps reduce ventricular remodeling and recovers functional aspects of the heart, such as LVEF, without necessarily reducing the IS.
To take dose into account for preclinical studies, we conducted a metaregression, which indicated that the number of MSCs delivered was not a significant predictor for IS and LVEF in the animal models, including specifically AMI swine models, which compared all 4 routes of delivery. Golpanian et al 20 concluded that the field of cell therapy lacks consistent and reliable evidence for dosage, with conflicting data for low versus high dose. Although some preclinical and clinical studies report that the number of cells administered is proportional to the observed clinical effect, other studies have yielded paradoxical results. Schuleri et al 34 studied an ICM swine model where MSCs were administered via DI and reported a significant reduction in IS with a high dose (200 million MSCs) compared with a low dose (20 million MSCs). In contrast to these findings, Hashemi et al 28 studied an AMI swine model with TESI as the route of delivery, which found that the lower doses (24 and 240 million MSCs) exhibited a significant decrease in IS, whereas the higher dose (440 million MSCs) did not. Future studies should use dose escalations with the different routes of delivery to assess the optimal number of MSCs to administer.
In addition, studies with fewer animals per group may be underpowered, whereas studies with more animals per group are likely more informative. Therefore, for purposes of this meta-analysis, the forest plots were weighted in terms of SD and sample size so that larger studies held more weight, to account for the studies that may have been underpowered. Even in the presence of underpowered studies, MSC therapy showed a favorable effect on reduction of IS and improvement of LVEF.
Furthermore, many animal studies showed large improvements of LVEF and IS, whereas other studies, including some clinical trials, showed improvements, but to a lesser extent. These parameters were analyzed as the primary end points because they were shared between the translational studies and the clinical trials. Other important end points were not described in all studies and were not included in this analysis. Several clinical trials, including POSEIDON 11 and TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure Trial), 12 reported that MSC therapy did not greatly improve LVEF 12-month poststem cell injection; however, significant improvements were seen in the clinical status of the patients, as measured by 6-minute walk test and Minnesota Living with Heart Failure questionnaire score. 10 Our study analyzed 1 structural (IS) and 1 functional (LVEF) parameter, but chronic ischemic cardiomyopathy is a complex disease with multiple mechanisms contributing to its pathology. After an MI, the heart is in an inflammatory state with microvascular disease, dysfunctional viable myocardium, wall stress, mitochondrial dysfunction, oxidative stress, increased apoptosis, and fibrosis. All of these changes lead to progressive, adverse LV remodeling. 35 MSCs, via their paracrine signaling and immunomodulatory properties, can attenuate the multiple pathways contributing to adverse LV remodeling. Therefore, we also analyzed FS, another measure of contractility, to help address the remodeling of the heart in ischemic cardiomyopathy. Similar to LVEF, there was an improvement in FS after MSC therapy. Further studies are needed to identify the mechanism(s) by which MSCs attenuate disease progression.
On the basis of the translational and clinical data, TESI seems to be a favorable method for administration of MSCs. The swine studies using TESI as the route of delivery revealed both a reduction in IS and improvement of LVEF, [25] [26] [27] a result reinforced by TESI providing an improvement of LVEF seen in the AMI clinical trials. 6 A future application would be to provide MSC therapy via TESI to patients who present with an AMI and undergo percutaneous coronary intervention, which, as our results suggest, will lead to a better clinical outcome.
Limitations
Our statistical analysis consisted of forest plots, which depicted differences between treatment and control. This type of analysis enabled us to assess whether certain routes of delivery were favorable, but it did not allow us to analyze the differences between groups. Also, as in all meta-analyses, heterogeneity must be taken into account. To eliminate some of the heterogeneity, we looked at subgroups, however, this approach reduced the number of studies analyzed per group, at times leaving only 1 study. Furthermore, not every study provided the SEM/SD, which did not allow us to include them in the analysis.
Also, the ISs showed great variability across some studies, specifically in rat models, which may have impacted the results because larger infarcts are more detrimental to cardiac function. To control for this variability, we calculated ΔIS to account for differences in baseline IS. We analyzed swine studies because they were the only ones to provide enough data for the calculations. Our analysis showed that MSC therapy had an equivalent reduction for ΔIS and IS at the final end points, giving us confidence in our results.
Although comparison of all 4 routes of delivery was conducted in acute swine studies, our analysis was limited in the murine and rodent studies because only DI and intravenous infusion were performed, as well as in human AMI trials where DI was not performed. In addition, because of the low number of ICM swine and human studies, we were not able to do subgroup analyses for the routes of delivery. Therefore, additional studies are needed to verify the best delivery route(s).
Conclusions
MSC therapy reduces IS and improves LVEF and cardiac function in both AMI and ICM animal models, supporting the use of MSC therapy. Furthermore, the route of delivery influences the efficacy of MSC therapy in preclinical and clinical studies. TESI seems to be the most favorable route of delivery because of its reduction in IS and improvement of LVEF in AMI preclinical and clinical trials, which has important implications for the design of future studies.
